Zelira Therapeutics Limited (ZLDAF)

Market Cap	2.90M
Revenue (ttm)	25.30K
Net Income (ttm)	-3.00M
Shares Out	n/a
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117
Average Volume	1,508
Open	0.2998
Previous Close	0.2873
Day's Range	0.2998 - 0.2998
52-Week Range	0.1912 - 0.5524
Beta	0.61
RSI	39.52
Earnings Date	May 27, 2025

About Zelira Therapeutics

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products un...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZLDAF

Financial Performance

In 2024, Zelira Therapeutics's revenue was 94,952, a decrease of -68.47% compared to the previous year's 301,121. Losses were -36.57 million, 556.2% more than in 2023.

Financial numbers in AUD